euro adhoc - Meldung

11.11.2008 - euroadhoc / Börse / stock market / Financial Figures / Balance Sheet / 9-month report
euro adhoc: Intercell AG / Financial Figures/Balance Sheet / Approvals for Japanese Encephalitis vaccine in U.S., Europe and Australia on track for 2008 - All development programs progressing according to plan - Profitability expected for full year 2008 - Strong financial and strategic position (E)=

--------------------------------------------------------------------------------
  Disclosure announcement transmitted by euro adhoc. The issuer is responsible
  for the content of this announcement.
--------------------------------------------------------------------------------
11.11.2008
Intercell successfully advanced parallel regulatory processes in all key markets
for travelers and military personnel - Vaccine against Japanese Encephalitis
expected to obtain market approval in the U.S., Europe and Australia in 2008 -
U.S. Defense Logistics Agency Request for Proposal (RFP) for purchase of
Japanese Encephalitis (JE) vaccine for U.S. military in negotiation
» United States: On October 20, the U.S. Food and Drug Administration 
  (FDA) gave positive feedback on Intercell's application to market its 
  vaccine against Japanese Encephalitis; Intercell and the agency are working 
  towards the earliest possible approval - ACIP meeting discussion on future 
  recommendation of JE vaccine held on October 22/23 with formal decision 
  expected at the February 2009 meeting
» Europe: Approval process advancing according to plan - Intercell expects a 
  positive opinion from EMEA in December 2008
» Australia: Positive approval decision is expected in December 2008
» Intercell has geared up manufacturing efforts to ensure timely product 
  delivery to the U.S. military by the end of 2008 and for commercial product 
  launch in the United States, Europe and Australia in early 2009
Integration of recent acquisition of IOMAI successfully implemented - Focus now
on aggressively progressing Travelers' Diarrhea patch vaccine and leveraging
patch-based products and technologies 
» Strategic focus on late-stage development and industrialization of the 
  Travelers' Diarrhea patch vaccine and Pandemic Influenza patch vaccine. In 
  addition, investigation of the use of the patch technology in new vaccine 
  applications has been effectively initiated
» Start of pivotal Phase III for Travelers' Diarrhea patch vaccine expected 
  in H1 2009
» Start of Phase II Pandemic flu vaccine expected in H1 2009
Nosocomial infections - S. aureus vaccine and Pseudomonas vaccine progressing in
clinical programs - All other development programs and partnerships on track
» Pseudomonas: Start of clinical Phase II/III trials in ventilated Intensive 
  Care Unit patients expected in December 2008
» S. aureus: Phase II study by Intercell's partner Merck & Co. Inc. in 
  cardiothoracic surgery progressing well with efficacy data expected by mid 
  2009 - further Phase II study initiated in hemodialysis patients with late-
  stage kidney disease, expanding the field of application of the vaccine
» Pneumococcus: After full preparation of clinical strategy, start of clinical 
  Phase I trials planned for early 2009
Results from 6-month follow-up of Intercell's therapeutic Hepatitis C vaccine
showed statistically significant and long-term antiviral effect in Phase II
patients
» Intercell is currently examining options for future development including 
  the formulation of the vaccine with IC31® and combination with other 
  antiviral therapies 
Therapeutic Monoclonal Antibodies
» Strategic partnering process initiated to extract maximum value out of this 
  franchise and to keep internal focus on vaccines
Financial Statements
» Intercell's aggregate revenues doubled from EUR 12.6 m in the 9 months ended 
  September 30, 2007 to EUR 25.3 m in the same period of 2008
» Intercell's net loss decreased by EUR 8.3 m, or 37.6 percent, to EUR 13.8 m 
  in the first 9 months of 2008 from EUR 22.1 m in the same period of 2007
» As of September 30, 2008 Intercell had liquid funds of EUR 209.0 m, of which 
  EUR 49.1 m was cash and EUR 159.9 m was available-for-sale financial assets
» Cash preservation is the principal goal of Intercell's short-term cash 
  management strategy. The impact of the current conditions in the capital 
  markets on the cash portfolio is therefore minimal
KEY FIGURES - FINANCIAL HIGHLIGHTS
EUR in thousands     3 months ended     9 months ended     Year ended
                    Sept 30,  Sept 30  Sept 30  Sept 30,     Dec 31,
                     2008      2007     2008     2007         2007
Revenues            7,641      7,375   25,283   12,559       53,349
Net profit/loss    (5,140)    (6,514) (13,789) (22,085)       5,009
Net operating
 profit/loss       24,956    (12,978)    (430) (27,480)      41,686
Cash and market-
 able securities,
 end of period    208,952    218,580  208,952  218,580      284,571

Further inquiry note:
Intercell AG 
Lucia Malfent
Head of Communications
Tel. +43 1 20620-1303
lmalfent@intercell.com
emitter:      Intercell AG
              Campus Vienna Biocenter  6
              A-1030 Wien 
phone:        +43 1 20620-0
FAX:          +43 1 20620-800
mail:         investors@intercell.com 
WWW:          www.intercell.com
sector:       Biotechnology
ISIN:         AT0000612601
indexes:      ATX Prime, ATX
stockmarkets: official market: Wiener Börse AG 
language:     English